2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Omics Technologies, Gene Editing, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Immunology, Neutropenia, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly
PAPER

5609 Outcomes after hypomethylating-agents failure in higher-risk myelodysplastic syndromes remain poor in the modern era: Salvage therapies represent an unmet need

Rami Komrokji, MD, Julie Braish, MD2, Rumana Tokaria, MD3, Najla Al Ali, MS4, Zhuoer Xie, MD,MS5, Rory Shallis, MD6, Andrew T Kuykendall, MD7, Samuel Benjamin Reynolds, MD8, Onyee Chan, MD9, Seongseok Yun, MD, PhD10, Kendra L. Sweet, MD, MS11, Alison Walker, MD12, Jeffrey Lancet, MD13, Eric Padron, MD14, David Sallman, MD15
1 Moffitt Cancer Center, Tampa, Florida, United States
2 Moffitt Cancer Center, Tampa, Florida, United States
3 Moffitt Cancer Center, Tampa, Florida, United States
4 Moffitt Cancer Center, Tampa, Florida, United States
5 Moffitt Cancer Center, Tampa, Florida, United States
6 Moffitt Cancer Center, Tampa, Florida, United States
7 Moffitt Cancer Center, Tampa, Florida, United States
8 Moffitt Cancer Center, Tampa, Florida, United States
9 Moffitt Cancer Center, Tampa, Florida, United States
10 Moffitt Cancer Center, Tampa, Florida, United States
11 Moffitt Cancer Center, Tampa, Florida, United States
12 Moffitt Cancer Center, Tampa, Florida, United States
13 Moffitt Cancer Center, Tampa, Florida, United States
14 Moffitt Cancer Center, Tampa, Florida, United States
15 Moffitt Cancer Center, Tampa, Florida, United States

Introduction:

Historically, overall survival (OS) after hypomethylating agents’ (HMA) failure in higher risk myelodysplastic syndromes (HRMDS) is poor with 4-6 months (mo) median OS. The last decade witnessed approval of several new therapies for acute myeloid leukemia (AML). We revisited outcomes after HMA failure and response to salvage treatment in this era.

Methods:

We identified all HRMDS patients (pts) defined by IPSS-M who received HMA as frontline therapy at Moffitt Cancer Center between 2010-2025, we examined outcomes after HMA failure and response to salvage treatment given with or without AML transformation.

Results:

Among 1042 HRMDS pts who received HMA or HMA/Venetoclax (V) upfront treatment, the median OS from time of diagnosis was 20.4 mo consistent with recent data from randomized clinical trials in the modern era. IPSS-M, TP53 mutation, and allogeneic stem cell transplant (AHSCT) were predictive of OS. From date of HMA failure, the median OS was 8.7 mo (2 yr-OS rate 23.8%). For 1st line therapy, 126 pts received HMA/V, the median OS from treatment failure was 8.3 mo compared to 8.8 mo for HMA alone (n=894), p=0.19.  Among pts who did not proceed to AHSCT after 1st line therapy, median OS was 3.4 mo after HMA/V (n=87) compared to 7.1 mo for HMA failure alone (n=721), p=0.053.

 HMA/V combination was 2nd line therapy among 26 pts who received HMA alone frontline therapy without AML transformation. The complete response (CR) rate was 11.5% and marrow CR (mCR) was 46.2%. The median OS for the whole group was 10.9 months (numerically higher for CR 29.7 mo (n=3) compared to 12 mo for mCR (n=12) and 5.5 mo for non-responders (n=11)). Only 6 pts proceeded to AHSCT (3 with CR/mCR and 3 with no response to HMA/ven) with 30.1 mo median OS.

Among pts who were treated with HMA alone as frontline therapy for HRMDS who progressed to AML at time of failure, 47 pts received HMA/V and 57 pts received intensive chemotherapy (IC) as AML treatment. The CR rate was higher with IC, 6.4% for HMA/V compared to 35.7% for IC, p < 0.005. The median OS was not different, 5.5 mo for HMA/V compared to 7.2 mo for IC, p=0.17.  Among those pts, 15 pts received AHSCT (12 after IC and 3 after HMA/V, 12/15 had response to treatment prior to transplant). The median OS was 26.5 mo for those who underwent AHSCT vs 4.9 mo for those who did not, p < 0.005.

Among 30 pts who received HMA/V frontline for HRMDS who progressed to AML and received any AML treatment, CR was 10% (3/30) and median OS 5.0 mo.

Conclusion

Outcome post HMA failure upfront treatment in HRMDS remains poor. Among pts without AML transformation, HMA/V combination had modest activity as second line therapy after HMA failure. For pts who transformed to AML, IC yields higher CR rates than HMA/V but no difference in OS. AHSCT remains the only option associated with improved OS post HMA failure. Outcomes were notably worse after HMA/V first line failure among those who did not proceed to AHSCT. Our study provides benchmark data for future clinical studies and highlights the unmet need for better therapies after HMA failure and emphasizes the important role of bridging to AHSCT.

Rami Komrokji, MD: Abbvie - Honoraria; syndax - Honoraria; Takeda - Honoraria; Stemline - Honoraria; DSI - Honoraria; BMS - Honoraria; GSK - Honoraria; RIGEL - Honoraria; Sobi - Honoraria; Kura - Honoraria; Servier - Honoraria; Novartis - Honoraria; Sumitomo - Honoraria; GERON - Honoraria; PharmaEssentia - Honoraria; BMS - Research Funding; Takeda - Consultancy (Includes expert testimony); RIGEL - Consultancy (Includes expert testimony); syndax - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); PharmaEssentia - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); DSI - Consultancy (Includes expert testimony); GERON - Consultancy (Includes expert testimony); Kura - Consultancy (Includes expert testimony); Stemline - Consultancy (Includes expert testimony); Sumitomo - Consultancy (Includes expert testimony)